MenB Vaccine Offers No Protection Against Gonorrhoea, Study Finds

Scientists have published findings from a major study concluding that the Meningitis B (MenB) vaccine does not offer protection against gonorrhoea infections in men, contradicting hopes that the vaccine might serve a dual purpose in preventing the sexually transmitted infection (STI).

The Research Findings

The MenB vaccine was previously offered to at-risk men — including men who have sex with men — partly on the basis of scientific interest in whether the vaccine might also provide protection against gonorrhoea. This interest arose from the biological relationship between Neisseria meningitidis, the bacterium targeted by the MenB vaccine, and Neisseria gonorrhoeae, the bacterium that causes gonorrhoea.

However, scientists now say the vaccine offers men no such protection. The study represents a significant finding for public health strategies aimed at combating rising rates of gonorrhoea, which has become an increasing concern in many countries due to antibiotic resistance.

Implications for Sexual Health Policy

Gonorrhoea is one of the most common sexually transmitted infections globally, and antibiotic-resistant strains have been identified in multiple countries, making prevention strategies increasingly important. The finding that MenB does not provide protection means that alternative approaches will need to be the focus of prevention efforts.

Health authorities are expected to review guidance following the publication of this research. The MenB vaccine will continue to be offered for its primary purpose of protecting against Meningitis B infections, which can be life-threatening.